Key facts
- This page summarizes Shankar Hariharan's Form 4 filing for Scienture Holdings, Inc. (SCNX).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2026, 21:32.
Shankar Hariharan - 19 Sep 2024 Form 4 Insider Report for Scienture Holdings, Inc. (SCNX)
- Reporting relationship
- Co-CEO & Chairman, Director, 10%+ Owner
- Issuer ticker
- SCNX
- Reported as of
- 19 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2026, 21:32:55 UTC
- Prior SEC filing
- 05 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kate L. Bechen, as attorney-in-fact for Shankar Hariharan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shankar Hariharan filed Form 4 for Scienture Holdings, Inc. (SCNX) on 12 Mar 2026.
Change
- Previous filing in this sequence was filed on 05 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002031316
Primary reporting owner
Shankar Hariharan
- Relationship
- Co-CEO & Chairman, Director, 10%+ Owner
- Address
- C/O SCIENTURE HOLDINGS, INC., 20 AUSTIN BLVD., COMMACK
- Signature
- /s/ Kate L. Bechen, as attorney-in-fact for Shankar Hariharan
- Signature date
- 12 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SCNX
transaction
Common Stock, par value $0.00001
Conversion of derivative security
- Transaction value
- Shares
- +1,916,816
- Change %
- +2341%
- Price
- Shares after
- 1,998,679
- Date
- 19 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
SCNX
transaction
Common Stock, par value $0.00001
Conversion of derivative security
- Transaction value
- Shares
- +356,480
- Change %
- +2342%
- Price
- Shares after
- 371,704
- Date
- 19 Sep 2024
- Ownership
- By Spouse
- Footnotes
- F1
SCNX
transaction
Common Stock, par value $0.00001
Other
- Transaction value
- Shares
- -30,000
- Change %
- -1.5%
- Price
- $0.000000*
- Shares after
- 1,968,679
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
SCNX
transaction
Common Stock, par value $0.00001
Award
- Transaction value
- Shares
- +750,000
- Change %
- +38%
- Price
- $0.000000*
- Shares after
- 2,718,679
- Date
- 14 Apr 2025
- Ownership
- Direct
- Footnotes
- F3
SCNX
transaction
Common Stock, par value $0.00001
Award
- Transaction value
- Shares
- +300,000
- Change %
- +11%
- Price
- $0.000000*
- Shares after
- 3,018,679
- Date
- 01 Oct 2025
- Ownership
- Direct
- Footnotes
- F4
SCNX
transaction
Common Stock, par value $0.00001
Award
- Transaction value
- Shares
- +500,000
- Change %
- +17%
- Price
- $0.000000*
- Shares after
- 3,518,679
- Date
- 20 Feb 2026
- Ownership
- Direct
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SCNX
transaction
Derivative
Series X Non-Voting Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,916,816
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.00001
- Underlying amount
- 1,916,816
- Exercise price
- Footnotes
- F1
SCNX
transaction
Derivative
Series X Non-Voting Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -356,480
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Sep 2024
- Ownership
- By spouse
- Underlying class
- Common Stock, par value $0.00001
- Underlying amount
- 356,480
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.
Footnote F2
These shares of Common Stock were transferred by Dr. Shankar Hariharan to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Hariharan, and certain other parties thereto.
Footnote F3
These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.
Footnote F4
These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.
Footnote F5
On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.